CVS Caremark Ordered to Pay $289.9 Million in FCA Action over Inflated Medicare Drug Payments
- August 22, 2025
Pharmacy Benefit Manager (PBM) CVS Caremark must pay $289.9 million in treble damages and civil penalties under the False Claims Act (FCA) for inflating the prices of Part D drugs, causing Medicare to over-subsidize drug costs, a U.S. District Court for the Eastern District of Pennsylvania said this week.
ARTICLE TAGS
You must be logged in to access this content.